The University of Southampton
University of Southampton Institutional Repository

A randomized crossover study comparing the antiplatelet effect of plavix versus generic clopidogrel

A randomized crossover study comparing the antiplatelet effect of plavix versus generic clopidogrel
A randomized crossover study comparing the antiplatelet effect of plavix versus generic clopidogrel
Background: Clopidogrel exists in different salt formulations. All published data that have demonstrated its beneficial effect are based entirely on the hydrogen sulphate salt contained in the branded product Plavix, which had US sales of $6.1 billion in 2010 alone. A number of cheaper generic versions of clopidogrel are increasingly being used in Europe as an alternative to Plavix, mainly for cost reasons. However, there is insufficient evidence to show that their pharmacodynamic effect is equivalent to Plavix.

Methods: This prospective study investigated whether there is any significant difference in the antiplatelet effect of Plavix versus generic clopidogrel hydrochloride in healthy male volunteers. All participants received loading and maintenance doses of both drugs, in a crossover manner, separated by a 2-week washout period. Adenosine diphosphate (ADP)-induced platelet reactivity was measured using short thrombelastography at multiple timepoints.

Results: The results showed interindividual heterogeneity in responses to clopidogrel but no significant difference in ADP-induced platelet reactivity between Plavix versus generic clopidogrel hydrochloride.

Conclusions: Our findings suggest comparable inhibition of ADP-induced platelet reactivity with Plavix and generic clopidogrel hydrochloride. This observation is particularly pertinent at a time when the patent for Plavix is expected to expire in the near future leading to the large-scale switch to cheaper generic preparations.

antiplatelet therapy, clopidogrel, platelet aggregation
0160-2446
495-501
Sambu, Nalyaka
7d0ba3fb-e39e-48d7-a0e4-ce249acc5980
Radhakrishnan, A.
3db27dff-d225-46da-97c5-c85cec618735
Curzen, N.
70f3ea49-51b1-418f-8e56-8210aef1abf4
Sambu, Nalyaka
7d0ba3fb-e39e-48d7-a0e4-ce249acc5980
Radhakrishnan, A.
3db27dff-d225-46da-97c5-c85cec618735
Curzen, N.
70f3ea49-51b1-418f-8e56-8210aef1abf4

Sambu, Nalyaka, Radhakrishnan, A. and Curzen, N. (2012) A randomized crossover study comparing the antiplatelet effect of plavix versus generic clopidogrel. Journal of Cardiovascular Pharmacology, 60 (6), 495-501. (doi:10.1097/FJC.0b013e31826f36bc). (PMID:23232787)

Record type: Article

Abstract

Background: Clopidogrel exists in different salt formulations. All published data that have demonstrated its beneficial effect are based entirely on the hydrogen sulphate salt contained in the branded product Plavix, which had US sales of $6.1 billion in 2010 alone. A number of cheaper generic versions of clopidogrel are increasingly being used in Europe as an alternative to Plavix, mainly for cost reasons. However, there is insufficient evidence to show that their pharmacodynamic effect is equivalent to Plavix.

Methods: This prospective study investigated whether there is any significant difference in the antiplatelet effect of Plavix versus generic clopidogrel hydrochloride in healthy male volunteers. All participants received loading and maintenance doses of both drugs, in a crossover manner, separated by a 2-week washout period. Adenosine diphosphate (ADP)-induced platelet reactivity was measured using short thrombelastography at multiple timepoints.

Results: The results showed interindividual heterogeneity in responses to clopidogrel but no significant difference in ADP-induced platelet reactivity between Plavix versus generic clopidogrel hydrochloride.

Conclusions: Our findings suggest comparable inhibition of ADP-induced platelet reactivity with Plavix and generic clopidogrel hydrochloride. This observation is particularly pertinent at a time when the patent for Plavix is expected to expire in the near future leading to the large-scale switch to cheaper generic preparations.

This record has no associated files available for download.

More information

Published date: December 2012
Keywords: antiplatelet therapy, clopidogrel, platelet aggregation
Organisations: Human Development & Health

Identifiers

Local EPrints ID: 355250
URI: http://eprints.soton.ac.uk/id/eprint/355250
ISSN: 0160-2446
PURE UUID: 085cae0d-8569-4f30-a1f2-2c2cf772e6d9
ORCID for N. Curzen: ORCID iD orcid.org/0000-0001-9651-7829

Catalogue record

Date deposited: 19 Aug 2013 12:53
Last modified: 15 Mar 2024 03:23

Export record

Altmetrics

Contributors

Author: Nalyaka Sambu
Author: A. Radhakrishnan
Author: N. Curzen ORCID iD

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×